Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Villejuif – page 49

929 clinical trials in Villejuif, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Villejuif at a glance
929
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

929 trials in Villejuif

Open in trial search

Study on Gemtuzumab Ozogamicin and Gilteritinib for Adults with Relapsed or Refractory Acute Myeloid Leukemia with FLT3 Mutation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Gilteritinib
  • Sponsor:Centre Antoine Lacassagne

Study on Ceralasertib and Trastuzumab Deruxtecan for Patients with Non-Small Cell Lung Cancer After Anti-PD-1/PD-L1 Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ceralasertib
  • Sponsor:AstraZeneca AB
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Zoledronic Acid Monohydrate
  • Sponsor:Unicancer

Study on the Safety and Effectiveness of IMGN151 for Women with Recurrent Endometrial and Ovarian Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Brimonidine Tartrate
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Glioblastoma

Not recruiting

Study on Durvalumab and Radiation Therapy for Patients with Recurrent Glioblastoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Oncopole Claudius Regaud

Neoplasm malignant

Not recruiting

Study of Lurbinectedin and Irinotecan for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Irinotecan
  • Sponsor:Pharma Mar S.A.

Breast cancer+7

Not recruiting

Study of Sacituzumab Govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:GBG Forschungs GmbH

Study of Itolizumab with Corticosteroids for Initial Treatment of Acute Graft Versus Host Disease in Patients After Bone Marrow Transplant

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Itolizumab
  • Sponsor:Equillium Inc.

Neuroblastoma+1

Not recruiting

Study of Palbociclib with Drug Combinations for Children and Young Adults with Recurrent or Refractory Neuroblastoma and Ewing Sarcoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Palbociclib
  • Sponsor:Pfizer Inc.

Thymoma malignant

Not recruiting

Study of Nivolumab and Ipilimumab for Patients with Type B3 Thymoma and Thymic Carcinoma After Chemotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Deafness

Not recruiting

Study on SENS-401 to Prevent Hearing Loss Caused by Cisplatin in Adults with Cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:R-Azasetron Besilate
  • Sponsor:Sensorion

Study of AMG 193 alone and combined with docetaxel for treatment of advanced MTAP-null solid tumors in adult patients

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amg 193
  • Sponsor:Amgen Inc.

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Villejuif

What the registry says about research in the country

01 Oncology - Head and Neck Cancer

Innovative research focusing on locally advanced head and neck squamous cell carcinoma treatments, including novel therapies combined with radiotherapy and immunotherapy approaches.

  • NBTXR3 with radiotherapy
  • EGFR-ADC therapy combinations
  • HPV-positive oropharyngeal cancer
02 Gastrointestinal Oncology

Studies targeting various digestive system cancers, with particular focus on pancreatic adenocarcinoma and advanced gastric cancer treatments.

  • Anti-CEACAM5 ADC therapy
  • Sotorasib combinations
  • Novel gastrointestinal cancer treatments
03 Hematologic Malignancies

Cutting-edge research in multiple myeloma treatment, exploring new combination therapies and maintenance approaches.

  • Elranatamab-lenalidomide therapy
  • Belantamab mafodotin combinations
  • T-cell lymphoma treatments
04 Lung Cancer Research

Comprehensive studies in both non-small cell lung cancer and small cell lung cancer, investigating targeted therapies and immunotherapy combinations.

  • Novel antibody-drug conjugates
  • Microbiome-based approaches
  • Targeted therapy combinations
05 Advanced Solid Tumors

Broad-spectrum research investigating novel treatments for metastatic solid tumors, including innovative therapeutic approaches and combination strategies.

  • PARG inhibitor studies
  • Targeted molecular therapies
  • Immunotherapy combinations
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.